ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
2,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
2,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
2,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
2,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2,9,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2,10,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
4,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
4,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
4,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
4,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
5,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
5,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
5,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
5,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
5,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
